Difference between revisions of "Breast Cancer Data FHIR IG Proposal"
Mark Kramer (talk | contribs) |
Mark Kramer (talk | contribs) |
||
Line 38: | Line 38: | ||
<!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the IG (optional) --> | <!-- Additional work groups that may have an interest in contributing to, or reviewing the content of the IG (optional) --> | ||
− | CIMI | + | Clinical Information Modeling Initiative (CIMI) |
==FHIR Development Project Insight ID== | ==FHIR Development Project Insight ID== |
Revision as of 17:28, 3 March 2018
Contents
- 1 Breast Cancer Data Logical Models and FHIR® Profiles
- 1.1 Owning work group name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 IG Purpose
- 1.7 Content location
- 1.8 Proposed IG realm and code
- 1.9 Maintenance Plan
- 1.10 Short Description
- 1.11 Long Description
- 1.12 Involved parties
- 1.13 Expected implementations
- 1.14 Content sources
- 1.15 Example Scenarios
- 1.16 IG Relationships
- 1.17 Timelines
- 1.18 When IG Proposal Is Complete
- 1.19 FMG Notes
Breast Cancer Data Logical Models and FHIR® Profiles
Owning work group name
Clinical Interoperability Council
Committee Approval Date:
Pending e-vote (expected week of 3/5)
Contributing or Reviewing Work Groups
Clinical Information Modeling Initiative (CIMI)
FHIR Development Project Insight ID
1363
Scope of coverage
The breast cancer data implementation guide covers oncology-specific data necessary support breast cancer, focusing first and foremost on data driving clinical decision-making for medical and surgical oncologists. The implementation guide is expected to incrementally cover a wide variety of clinical domains (e.g. anatomic pathology, radiology), while supporting secondary data use in for clinical research, cancer registry reporting.
The first iteration of this guide is focused on breast cancer staging. Because staging information is largely driven by the American Joint Committee on Cancer, which is used in the US.
IG Purpose
The purpose of this implementation guide is to provide detailed clinical models and FHIR Profiles that are required to support reliable and consistent capture and exchange of interoperable medical records in the oncology domain. Applications such as clinical decision support, clinical quality measures, evidence-based and precision medicine all require a standardized specification for computable data elements (aka clinical models). This implementation guide will provide FHIR-based representations of standardized oncology data to support these applications.
Content location
We are in the process of including the content into the HL7 github repository. A superset of the profiles we intend to publish as part of the Breast Cancer FHIR IG can be found at [[1]]. Please note the FHIR IG we intend to publish will contain only oncology related content (SHR namespace: oncology). The first iteration of the IG will be constrained to the domain of breast cancer staging.
need to add path within the HL7 github repository or Simplifier project name.
Proposed IG realm and code
us/breastcancer
Maintenance Plan
A maintenance plan for this IG is yet to be discussed, as this is the first iteration of the document, which is essentially aimed at documenting requirements for breast cancer data elements.
Short Description
This IG contains a subset of logical models for breast cancer focused on data elements used for breast cancer staging. FHIR profiles are provided as an example physical representation of the logical models. Terminology bindings are preliminary, and in some cases, defined in terms of local codes only.
Long Description
Involved parties
This IG is being created through an informal collaboration of wide range of organizations and individual contributors that are part of the Cancer Interoperability Group, which includes representatives from the HSPC, AJCC, NCCN, CiiC, ACS, various health IT vendors, among many others.
Committed organizations include the MITRE Corporation and PenRad.
Expected implementations
MITRE and PenRad.
Content sources
Specifications consulted for the development of this IG include:
- American Joint Committee on Cancer Staging Manual (8th Edition)
- College of American Pathologists Cancer Protocols
- NAACR 2018 Site-Specific Data Items Manual (DRAFT)
- HL7 CDA R2 IG: Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers
- HL7 CDA R2 IG: Clinical Oncology Treatment Plan and Summary
Example Scenarios
- Capture of staging information by providers in EHR systems
- Transmission of anatomic pathologic reports
- Reporting to cancer registries
- Reporting for clinical trials
IG Relationships
No dependencies identified at present.
Timelines
- For Comment May 2018 Ballot
- For Comment September 2018 Ballot
- STU May 2019 Ballot
When IG Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org